News|Articles|December 10, 2014

Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers

Key Takeaways

Immunotherapy advancements in hematological cancers, especially Hodgkin lymphoma, show promising potential for treatment improvements.
The American Society of Hematology's annual meeting highlighted significant progress in blood cancer research.
Lee Greenberger emphasized the importance of continued research and innovation in immunotherapy for hematological malignancies.

Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.

Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies. The latest in blood cancer research, including studies involving immunotherapy for Hodgkin lymphoma, were announced at the annual meeting of the American Society of Hematology.